Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-Label, Multi-Center Study of ZN-c3 Administered in Combination with Encorafenib and Cetuximab in Adults with Metastatic Colorectal Cancer

Next Previous
Search
Trial Profile

A Phase 1/2, Open-Label, Multi-Center Study of ZN-c3 Administered in Combination with Encorafenib and Cetuximab in Adults with Metastatic Colorectal Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azenosertib (Primary) ; Cetuximab (Primary) ; Encorafenib (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors K-Group Beta

Most Recent Events

  • 23 Apr 2025 According to a Zentalis Pharmaceuticals media release, ASCO poster containing data from this trial can be accessed through the Supporting Publications tab on the Our Approach section of the Zentalis website on the day of the presentation
  • 23 Apr 2025 According to a Zentalis Pharmaceuticals media release, the company will present data from this study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
  • 25 Mar 2025 According to a Zentalis Pharmaceuticals media release, the company will present data from this study at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, IL.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top